Sector: Chemicals

Latest content

Brazilian Senate passes compulsory covid-19 know-how licensing bill

Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress

04 May 2021

Hatch-Waxman litigation defendants get taxation boost

A ruling handed down by the US Tax Court this week suggests generics can deduct legal fees for ANDA litigation

29 April 2021

Why high-tech patent expertise will be increasingly valued by life sciences companies

If the experience of NantWorks’ IP chief Mark Kokes is anything to go by, leading strategists from other sectors can make a splash in pharma and biotech

24 April 2021

SCOTUS looks likely to limit the assignor estoppel doctrine

Yesterday’s hearing in Minerva Surgical v Hologic is likely to have big implications for transactions and assignee-assignor disputes

22 April 2021

Korean Supreme Court tears up tough inventiveness standard

Life sciences innovators set to benefit from landmark Eliquis decision

15 April 2021

Brazil suspends drug patent extensions and reschedules key Supreme Court hearing for tomorrow

Long-running constitutional challenge putting 40% of patents at-risk set to be resolved, but further delays are possible

13 April 2021

French SPC rulings give first signs of Royalty Pharma’s impact

Paris Court of Appeal turns down three appeals over supplementary protection certificate rejections

12 April 2021

Six takeaways from the $1.8 billion finale to the LG Energy Solutions - SK Innovation IP dispute

As political wrangling and potential for commercial fallout mounted, the two Korean battery suppliers reached an eleventh-hour settlement deal yesterday

12 April 2021

Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

Hub-and-spokes life sciences companies are providing new opportunities for IP monetisation

08 April 2021

Pharma companies must factor tough standing requirements into IPR strategies

SCOTUS petition denial in Argentum v Novartis highlights the difficult choices facing those who wish to challenge patents at the PTAB

06 April 2021

Unlock unlimited access to all IAM content